{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:25:21Z","timestamp":1793258721421,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,7]]},"DOI":"10.1093\/eurheartj\/ehx317","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T07:09:41Z","timestamp":1495696181000},"page":"1162-1168","source":"Crossref","is-referenced-by-count":114,"title":["Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol"],"prefix":"10.1093","volume":"39","author":[{"given":"Gilbert R","family":"Thompson","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Medicine, Imperial College London, Hammersmith Campus, Ducane Road, London W12\u20090NN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J","family":"Blom","sequence":"additional","affiliation":[{"name":"Division of Lipidology, Department of Medicine, UCT Faculty Health Sciences, University of Cape Town, Anzio Road, 7925 Observatory, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A David","family":"Marais","sequence":"additional","affiliation":[{"name":"Division of Chemical Pathology, Department of Pathology, UCT Faculty Health Sciences, University of Cape Town, Anzio Road, 7925 Observatory, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Seed","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian J","family":"Pilcher","sequence":"additional","affiliation":[{"name":"Carbohydrate and Lipid Metabolism Research Unit, Department of Medicine, University of the Witwatersrand, 7 York Rd, Parktown 2193, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J","family":"Raal","sequence":"additional","affiliation":[{"name":"Carbohydrate and Lipid Metabolism Research Unit, Department of Medicine, University of the Witwatersrand, 7 York Rd, Parktown 2193, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"key\n\t\t\t\t20180407055359_ehx317-B1","first-page":"2863","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Goldstein","year":"2001","edition":"8th ed"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/hrt.80.6.583","article-title":"Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia","volume":"80","author":"Rallidis","year":"1998","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","article-title":"Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry","volume":"10","author":"Alonso","year":"2016","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B5","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/bmj.291.6510.1671","article-title":"Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange","volume":"291","author":"Thompson","year":"1985","journal-title":"Br Med J Clin Res Ed"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B6","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosissup.2015.02.002","article-title":"Managing homozygous familial hypercholesterolaemia from cradle to grave","volume":"18","author":"Thompson","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2015.01.007","article-title":"Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia","volume":"239","author":"Lefort","year":"2015","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B9","doi-asserted-by":"crossref","first-page":":1208","DOI":"10.1016\/S0140-6736(75)92193-5","article-title":"Plasma exchange in the management of homozygous familial hypercholesterolaemia","volume":"1","author":"Thompson","year":"1975","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B10","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jacl.2011.04.001","article-title":"National lipid association expert panel on familial hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Ito","year":"2011","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","article-title":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","volume":"255","author":"France","year":"2016","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2015.09.029","article-title":"Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes","volume":"243","author":"Thompson","year":"2015","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0021-9150(97)00168-8","article-title":"Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia","volume":"135","author":"Raal","year":"1997","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(99)00435-9","article-title":"Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolemia","volume":"150","author":"Raal","year":"2000","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.atherosclerosis.2007.06.028","article-title":"A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolemia","volume":"197","author":"Marais","year":"2008","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B16","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1172\/JCI0216445","article-title":"Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1","volume":"110","author":"Eden","year":"2002","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2006.10.003","article-title":"Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic","volume":"194","author":"Tosi","year":"2007","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B18"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.atherosclerosis.2016.03.009","article-title":"Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study","volume":"248","author":"Raal","year":"2016","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0021-9150(79)90101-1","article-title":"Heterozygous familial hypercholesterolemia. relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women","volume":"34","author":"Gagn\u00e9","year":"1979","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B22","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","article-title":"Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia","volume":"322","author":"Seed","year":"1990","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2017.01.015","article-title":"Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France","volume":"257","author":"Bruckert","year":"2017","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B26","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B27","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B28","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key\n\t\t\t\t20180407055359_ehx317-B29","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/39\/14\/1162\/24554016\/ehx317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T05:54:08Z","timestamp":1523080448000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/39\/14\/1162\/3896244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":29,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2017,7,1]]},"published-print":{"date-parts":[[2018,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx317","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,7]]},"published":{"date-parts":[[2017,7,1]]}}}